2004
DOI: 10.1111/j.1523-1755.2004.00781.x
|View full text |Cite
|
Sign up to set email alerts
|

Peripheral blood dendritic cells and GM-CSF as an adjuvantfor hepatitis B vaccination in hemodialysis patients

Abstract: GM-CSF is an effective adjuvant for hepatitis B vaccination in primary nonresponding hemodialysis patients, but paradoxically decreases the antigen presenting capacity of peripheral blood mononuclear cells and the number of circulating dendritic cells.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

3
57
1

Year Published

2007
2007
2022
2022

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 70 publications
(61 citation statements)
references
References 30 publications
3
57
1
Order By: Relevance
“…The prematurely aged T cell system of ESRD patients is associated with a reduced vaccination response (11)(12)(13)(14) and an increased susceptibility to infection (15). The latter is a major cause of mortality in ESRD patients, in addition to cardiovascular disease (15)(16)(17).…”
Section: Introductionmentioning
confidence: 99%
“…The prematurely aged T cell system of ESRD patients is associated with a reduced vaccination response (11)(12)(13)(14) and an increased susceptibility to infection (15). The latter is a major cause of mortality in ESRD patients, in addition to cardiovascular disease (15)(16)(17).…”
Section: Introductionmentioning
confidence: 99%
“…An aged T cell system is associated with an impaired immune response and contributes to a decreased vaccination response, greater susceptibility to infections and virus-associated cancers (9)(10)(11)(12)(13). CD4 þ CD28null T cells are highly cytotoxic and associated with an increased risk of atherosclerotic event (14,15), while the presence of highly differentiated CD8 þ T cells impairs renal graft function on the long term (16).…”
Section: Introductionmentioning
confidence: 99%
“…The dermal dendritic cell in the skin was speculated as one of the most potent antigen-presenting cell leading to primary immune response. [10] However, in a recent study, there was no difference between those two routes of administration. [11] In this study, after two 40 μg intramuscular (IM) vaccination protocols (0, 1, 2, and 6 months), patients who were unresponsive to hepatitis B vaccination were collected from three HD centers.…”
Section: Introductionmentioning
confidence: 90%
“…[1,10,12,13] However, cost-effectiveness has been another problem that needed to be addressed. Vaccination for hepatitis B at early stages of chronic kidney disease was found to reach seroprotective ranges more successfully in a previous study.…”
mentioning
confidence: 99%